UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 134

Sortiert nach

Retraction Note: IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer

Oncogene, 2024-04, Vol.43 (16), p.1231-1231

2024

Volltextzugriff (PDF)

IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer

Oncogene, 2013-01, Vol.32 (2), p.151-159

2013

Volltextzugriff (PDF)

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma

Oncogene, 2016-06, Vol.35 (24), p.3209-3216

2016

Volltextzugriff (PDF)

Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells

Oncogene, 2003-07, Vol.22 (27), p.4150-4165

2003

Volltextzugriff (PDF)

Stat3 regulates genes common to both wound healing and cancer

Oncogene, 2005-05, Vol.24 (21), p.3397-3408

2005

Volltextzugriff (PDF)

RETRACTED ARTICLE: IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer

Oncogene, 2013-01, Vol.32 (2), p.151-159

2013

Volltextzugriff (PDF)

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing

JNCI : Journal of the National Cancer Institute, 2014-09, Vol.106 (9), p.dju250-dju250

2014

Volltextzugriff (PDF)

Dissecting the landscape of CAF-mediated drug resistance mechanisms in ALK-rearranged NSCLC

European journal of cancer (1990), 2020-10, Vol.138, p.S48-S48

2020

Volltextzugriff (PDF)

Prospective Phase I/II Study of Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLC

International journal of radiation oncology, biology, physics, 2021-11, Vol.111 (3), p.S3-S4

2021

Volltextzugriff (PDF)

Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer

Nature clinical practice. Oncology, 2005-06, Vol.2 (6), p.315-324

2005

Volltextzugriff (PDF)

Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics

Molecular cancer therapeutics, 2014-11, Vol.13 (11), p.2751-2762

2014

Volltextzugriff (PDF)

MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion

International journal of oncology, 2009-08, Vol.35 (2), p.337-345

2009

Volltextzugriff (PDF)

Activated Epidermal Growth Factor Receptor–Stat-3 Signaling Promotes Tumor Survival In vivo in Non–Small Cell Lung Cancer

Clinical cancer research, 2005-12, Vol.11 (23), p.8288-8294

2005

Volltextzugriff (PDF)

Direct repression of the Mcl-1 promoter by E2F1

Oncogene, 2002-02, Vol.21 (9), p.1359-1369

2002

Volltextzugriff (PDF)

Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells

Cancer biology & therapy, 2005-03, Vol.4 (3), p.267-276

2005

Volltextzugriff (PDF)

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors

OncoTargets and therapy, 2017-01, Vol.10, p.4239-4250

2017

Volltextzugriff (PDF)

Gene therapy for lung cancer

Molecular biotechnology, 2003-10, Vol.25 (2), p.139-148

2003

Volltextzugriff (PDF)

Dasatinib in solid tumors

Expert opinion on investigational drugs, 2010-03, Vol.19 (3), p.415-425

2010

Volltextzugriff (PDF)

EGR1 Predicts PTEN and Survival in Patients With Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-03, Vol.23 (9), p.1921-1926

2005

Volltextzugriff (PDF)

Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies

Cancer control, 2001-07, Vol.8 (4), p.326-336

Haura, E B

2001

Volltextzugriff (PDF)

Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1

Molecular cancer therapeutics, 2003-01, Vol.2 (1), p.73-81

2003

Volltextzugriff (PDF)

Direct repression of the Mcl-1 promoter by E2F1

Oncogene, 2002-02, Vol.21 (9), p.1359-1369

2002

Volltextzugriff (PDF)

Phase I study of LBH589 in combination with erlotinib for advanced aerodigestive tract cancers

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13016-e13016

2010

Volltextzugriff (PDF)

Effect of dasatinib, a SRC kinase inhibitor, on lung cancer cells with defined epidermal growth factor receptor status

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.3019-3019

2006

Volltextzugriff (PDF)

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC)

Journal of clinical oncology, 2011-06, Vol.29 (18_suppl), p.CRA7506-CRA7506

2011

Volltextzugriff (PDF)

1 – 25 von 134

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(126)

Publikationsform

Artikel
(134)

Sprache

Englisch
(134)
Japanisch
(20)

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Life Sciences & Biomedicine
(60)
Humans
(56)
Oncology
(45)
Lung Cancer
(34)
Female
(25)
Lung Neoplasms - Genetics
(25)
Lung Neoplasms - Drug Therapy
(24)
Male
(24)
Lung Neoplasms - Pathology
(21)
Middle Aged
(20)
Aged
(19)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(17)
Cancer
(16)
Adult
(14)
Tumors
(14)
Animals
(13)
Biochemistry & Molecular Biology
(12)
Carcinoma, Non-Small-Cell Lung - Genetics
(12)
Cell Biology
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Retraction Note: IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer

IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma

Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells

Stat3 regulates genes common to both wound healing and cancer

RETRACTED ARTICLE: IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer

Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing

Dissecting the landscape of CAF-mediated drug resistance mechanisms in ALK-rearranged NSCLC

Prospective Phase I/II Study of Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable NSCLC

Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer

Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics

MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion

Activated Epidermal Growth Factor Receptor–Stat-3 Signaling Promotes Tumor Survival In vivo in Non–Small Cell Lung Cancer

Direct repression of the Mcl-1 promoter by E2F1

Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors

Gene therapy for lung cancer

Dasatinib in solid tumors

EGR1 Predicts PTEN and Survival in Patients With Non–Small-Cell Lung Cancer

Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies

Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1

Direct repression of the Mcl-1 promoter by E2F1

Phase I study of LBH589 in combination with erlotinib for advanced aerodigestive tract cancers

Effect of dasatinib, a SRC kinase inhibitor, on lung cancer cells with defined epidermal growth factor receptor status

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC)

Suchergebnisse filtern